+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

NTBC and alkaptonuria

American Journal of Human Genetics 63(3): 920-921

NTBC and alkaptonuria

An alternative therapy for alkaptonuria that avoids the problem of gene localization is described. The signs and symptoms of alkaptonuria are thought to be caused by homogentisic acid (HA). The treatment involves the oral administration of the triketone herbicide 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) combined with some dietary restriction of phenylalanine and tyrosine. As triketone herbicides inhibit 4-hydroxyphenylpyruvate dioxygenase, which is the enzyme that produces HA, therapy with NTBC should prevent HA production.

Accession: 009919776

PMID: 9718357

DOI: 10.1086/302027

Download PDF Full Text: NTBC and alkaptonuria

Related references

Making the diagnosis of alkaptonuria Unusual skin findings in an alkaptonuria patient. American Journal of Human Genetics 73(5): 447, November, 2003

Some Data On The Clinical Picture Of Alkaptonuria. Modified Method For The Determination Of Alkaptonuria And Homogentisic Acid. Orvosi Hetilap 105: 1359-1361, 1964

Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment. Annals of the Rheumatic Diseases 75(2): 362-367, 2016

Nitisinone. Ntbc, Orfadin. Drugs in R&d 3(2): 139-140, 2002

Tyrosinaemia type I and NTBC -1,3-cyclohexanedione. Journal of Inherited Metabolic Disease 21(5): 507-517, 1998

Corneal opacities associated with NTBC treatment. American Journal of Ophthalmology 134(2): 266-268, August, 2002

Quantitation of NTBC in plasma of patients with tyrosinemia by LC-ESI-MS/MS. Journal of Inherited Metabolic Disease 26(Supplement 2): 198, September, 2003

Does NTBC modulate D-serine-induced nephrotoxicity?. Toxicology Letters (Shannon) 144(Suppl 1): s96, September, 2003

Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). Journal of Inherited Metabolic Disease 21(5): 507-517, 1998

Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC. Journal of Inherited Metabolic Disease 26(1): 13-16, 2003